Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy

European Heart Journal, Supplement

Volumn 4, Issue I, 2002, Pages

  Felix, S B ^a   Staudt, A ^a   Baumann, G ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibodies; Dilated cardiomyopathy; Humoral immune system; Immunoadsorption

Indexed keywords

ANTIVIRUS AGENT; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; HEART ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; SPIRONOLACTONE; STEROID;

CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG MEGADOSE; HEART DILATATION; HEART MUSCLE CONTRACTILITY; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

EID: 0036900976     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90113-6     Document Type: Conference Paper

References (47)

1. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-2.
2. Feldman AM, McNamara DM. Myocarditis. N Engl J Med 2000; 343: 1388-98.
3. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104: 1076-82.
4. Kühl U, Noutsias M, Schultheiss HP. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J 1995; 16(suppl O): 100-6.
5. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, et al. Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J 1998; 19: 1564-72.
6. Noutsias M, Seeberg B, Schultheiss HP, Kühl U. Expression of cell adhesion molecules in dilated cardiomyopathy: Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-31.
7. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T-cell mediated disease. J Immunol 1991; 147: 2141-7.
8. Klappacher G, Mundigler G, Papousek A, et al. Elevated circulating levels of beta-2 microglobulin in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71: 119-22.
9. Limas CJ, Goldenberg IF, Limas C. Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies. Circulation 1995; 91: 631-4.
10. Schulze K, Becker BF, Schauer R, Schultheiss HP. Antibodies to ADP-ATP carrier - An autoantigen in myocarditis and dilated cardiomyopathy - Impair cardiac function. Circulation 1990; 81: 959-69.
11. Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734-42.
12. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64: 97-103.
13. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760-7.
14. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91: 1964-8.
15. Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J. A synthetic peptide corresponding to the second extracellular loop of the human M2 acetylcholine receptor induces pharmacological and morphological changes in cardiomyocytes by active immunization after 6 months in rabbits. Clin Immunol Immunopathol 1996; 78: 203-7.
16. Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646-5.
17. Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29: 641-55.
18. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
19. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-6.
20. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-86.
21. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
22. Aukrust P, Damas JK, Gullestad L, Froland SS. Chemokines in myocardial failure - Pathogenic importance and potential therapeutic targets. Clin Exp Immunol 2001; 124: 343-5.
23. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Cardiac Failure 1996; 2: 243-9.
24. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998; 30: 215-23.
25. Bozkurt B, Kribbs S, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-91.
26. Kubota T, McTierman CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor-α. Circ Res 1997; 81: 627-35.
27. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287: 628-40.
28. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6.
29. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (enbrel) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.
30. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICON, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-7.
31. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-8.
32. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269-75.
33. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: Two-year follow-up results. Circulation 2001; 104: 39-45.
34. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986; 1: 1120-3.
35. Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987; 84: 6272-6.
36. Jin O, Sole MJ, Butany JW, et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation 1990; 82: 8-16.
37. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999; 99: 1348-54.
38. Maisch B, Hufnagel G, Schönian U, Hengstenberg C. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995; 16(suppl O): 173-5.
39. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-16.
40. Godeau B, Lesage S, Divine M, Wirquin V, Farcet J, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82: 1415-21.
41. Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365-8.
42. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
43. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-9.
44. Dörffel WV, Felix SB, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994-7.
45. Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-8.
46. Müller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-91.
47. Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-6.